IOL CHEMICALS & PHARMACEUTICALS LTD.

A minor fire occurred at IOL Chemicals & Pharmaceuticals Ltd's Minoxidil manufacturing unit (Unit-9B) on June 9, 2026. No injuries were reported, and no significant damage to plant or property occurred. Operations at Unit-9B are suspended for 8-10 days for inspection and restoration. Other units are unaffected. A detailed investigation is underway. The company's assets are adequately insured, and the overall impact on operations is not expected to be significant.

IOL Chemicals & Pharmaceuticals Ltd. announced its FY26 results, reporting its highest-ever quarterly revenue. Revenue from operations for FY26 stood at ₹2319.1 Cr, an 11.5% increase YoY. EBITDA for FY26 was ₹290.4 Cr, up 29.3% YoY, with an EBITDA margin of 12.4%. PAT for FY26 reached ₹137.7 Cr, a 36.4% increase YoY. The company incurred capex of around ₹164 crore towards capacity expansion and other improvements.

The Board of Directors of IOL Chemicals & Pharmaceuticals Ltd addressed a one-day delay in filing the shareholding pattern for the quarter ended December 31, 2025, with BSE Limited. While the filing was submitted to the National Stock Exchange of India Limited on time, an oversight regarding the single-window filing mechanism led to the delay on the BSE portal. The company paid a fine of ₹2,000 levied by BSE. The Board has advised management to strengthen internal compliance monitoring.

IOL Chemicals & Pharmaceuticals Ltd. announced the fixing of its 39th Annual General Meeting (AGM) on September 2, 2026, to be held via video conferencing. The register of members and share transfer books will be closed from August 27, 2026, to September 2, 2026, for the AGM. The board also approved the installation of a new plant for manufacturing Triacetin with an initial capacity of 6000 MTPA and the enhancement of Pantoprazole production capacity from 240 MTPA to 276 MTPA, funded through internal accruals. Audited financial results for the year ended March 31, 2026, with an unmodified opinion from the statutory auditors, were also approved.

IOL Chemicals & Pharmaceuticals Ltd. announced the approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board has fixed the 39th Annual General Meeting (AGM) on September 2, 2026, via video conferencing. Additionally, the company approved the installation of a plant for manufacturing 'Triacetin' (6000 MTPA capacity) and enhancement of Pantoprazole production capacity from 240 MTPA to 276 MTPA, funded through internal accruals.

IOL Chemicals & Pharmaceuticals Ltd's board approved the audited standalone and consolidated financial results for the year ended March 31, 2026. The audit reports, issued by Ashwani & Associates, Chartered Accountants, contained an unmodified opinion. The 39th Annual General Meeting is scheduled for September 2, 2026, via video conferencing. The company also approved the installation of a plant for manufacturing Triacetin (6000 MTPA capacity in Phase-I) and enhanced the installed capacity of Pantoprazole from 240 MTPA to 276 MTPA, funded through internal accruals.

IOL Chemicals & Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 20, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The trading window, which has been closed since April 1, 2026, will remain closed until 48 hours after the results are made public, reopening on May 23, 2026.

IOL Chemicals & Pharmaceuticals Ltd. has received an order confirming a demand for differential customs duty of ₹27,97,398, along with applicable interest and penalties totaling ₹2,05,94,796. The demand arises from alleged incorrect availment of ASEAN-India FTA exemption due to non-conforming Certificates of Origin. The company intends to file an appeal against the order. The company believes this levy does not have any material impact on its financials or operations.

IOL Chemicals & Pharmaceuticals Ltd has joined the 'Saksham Niveshak' campaign initiated by the Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs. The campaign, which commences on 1st April 2026 and ends on 9th July 2026, aims to reach out to shareholders with unpaid or unclaimed dividends and assist them in claiming their dues. The company is also encouraging shareholders to update their KYC details to prevent the transfer of unclaimed dividends and corresponding shares to the Investor Education and Protection Fund (IEPF).

IOL Chemicals & Pharmaceuticals Ltd has announced that the Registrar of Companies has approved the application of striking off the name of its wholly owned subsidiary, IOL Life Sciences Limited. The subsidiary had applied for striking off its name from the records of Registrar of Companies on 27th January 2026. This decision does not have any material impact on the financials or operations of the Company.